Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?

Simply Wall St.07-09

In late June 2026, BioCryst Pharmaceuticals said it would discontinue its internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence by the end of 2026, shifting its ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650392271?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-09 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650392271","market":"hk","top_or_hot":-1,"title":"Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?","media":"Simply Wall St.","content":"<div>\n<p>In late June 2026, BioCryst Pharmaceuticals said it would discontinue its internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence by the end of 2026, shifting its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/is-biocryst-bcrx-trading-internal-discovery-for-a-more-durab\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs BioCryst (BCRX) Trading Internal Discovery for a More Durable Rare-Disease Innovation Model?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-09 20:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/is-biocryst-bcrx-trading-internal-discovery-for-a-more-durab><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late June 2026, BioCryst Pharmaceuticals said it would discontinue its internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence by the end of 2026, shifting its ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/is-biocryst-bcrx-trading-internal-discovery-for-a-more-durab\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/is-biocryst-bcrx-trading-internal-discovery-for-a-more-durab","article_id":"2650392271","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/is-biocryst-bcrx-trading-internal-discovery-for-a-more-durab","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650392271","pubTimestamp":1783600115,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late June 2026, BioCryst Pharmaceuticals said it would discontinue its internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence by the end of 2026, shifting its rare disease pipeline development toward external innovation and partnerships.\nThis move marks a major change in how BioCryst sources future drug candidates, trading in-house research infrastructure for a more flexible, partner-driven model that could reshape its long-term pipeline mix.\nNext,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药","BK4139":"生物科技","BK4547":"WSB热门概念"},"translate_title":"BioCryst␠(BCRX)␠是否正在用内部发现换取更持久的罕见病创新模式？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1.5},"content_text":"In late June 2026, BioCryst Pharmaceuticals said it would discontinue its internal discovery programs and close its Birmingham, Alabama Discovery Center of Excellence by the end of 2026, shifting its rare disease pipeline development toward external innovation and partnerships. This move marks a major change in how BioCryst sources future drug candidates, trading in-house research infrastructure for a more flexible, partner-driven model that could reshape its long-term pipeline mix. Next, we’ll consider how BioCryst’s decision to end internal discovery and pivot to external innovation might reshape its existing investment narrative. Outshine the giants: these 16 early-stage AI stocks could fund your retirement.AdvertisementBioCryst Pharmaceuticals Investment Narrative RecapTo own BioCryst today, you need to believe that ORLADEYO and a focused rare disease franchise can support the business while externally sourced assets refresh the pipeline. The shift away from internal discovery does not change the near term focus on ORLADEYO execution and key data and regulatory milestones, but it does increase uncertainty around long term research productivity and the company’s ability to replace its lead asset over time. The closure of the Birmingham Discovery Center closely ties into BioCryst’s plan to build its next wave of rare disease drugs through partnerships and in-licensing, rather than homegrown discovery. That matters when you think about upcoming catalysts for programs like navenibart and any future deals, because it puts more weight on the company’s external BD track record and capital allocation, and less on its historical discovery engine. Yet behind the recent optimism, investors should still pay close attention to how BioCryst manages its reliance on ORLADEYO and the risks around future pipeline diversification... Read the full narrative on BioCryst Pharmaceuticals (it's free!)BioCryst Pharmaceuticals’ narrative projects $930.1 million revenue and $131.3 million earnings by 2029. This requires 1.6% yearly revenue growth and a $589.3 million earnings increase from -$458.0 million today.Uncover how BioCryst Pharmaceuticals' forecasts yield a $21.30 fair value, a 92% upside to its current price.Exploring Other PerspectivesBCRX 1-Year Stock Price Chart Some analysts were far more optimistic before this shift, expecting revenue to reach about US$1.0 billion and earnings of roughly US$346.0 million by 2029, assuming BioCryst could keep expanding its rare disease pipeline despite the concentration risk around ORLADEYO; this new external innovation pivot might either reinforce or challenge that view, so it is worth comparing these bullish assumptions with more cautious takes to see where you stand.Explore 4 other fair value estimates on BioCryst Pharmaceuticals - why the stock might be worth over 7x more than the current price!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free BioCryst Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioCryst Pharmaceuticals' overall financial health at a glance.Searching For A Fresh Perspective?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioCryst Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650392271","isCrawlerRequest":true}